Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer

BACKGROUND: Although predictive value of immune‐related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) have been suggested by several studies, their assessments were insufficient because patients were categorized only by the occurrence of irAEs. It has not been elucidated whet...

Descripción completa

Detalles Bibliográficos
Autores principales: Akamatsu, Hiroaki, Murakami, Eriko, Oyanagi, Jun, Shibaki, Ryota, Kaki, Takahiro, Takase, Eri, Tanaka, Masanori, Harutani, Yuhei, Yamagata, Nao, Okuda, Yuka, Furuta, Katsuyuki, Sugimoto, Takeya, Teraoka, Shunsuke, Hayata, Atsushi, Tokudome, Nahomi, Ozawa, Yuichi, Mori, Keita, Koh, Yasuhiro, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Immuno‐Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160399/
https://www.ncbi.nlm.nih.gov/pubmed/32297443
http://dx.doi.org/10.1634/theoncologist.2019-0299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160399/
https://www.ncbi.nlm.nih.gov/pubmed/32297443
http://dx.doi.org/10.1634/theoncologist.2019-0299

Ejemplares similares